Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis

[1] Seeff LB(1992)Long-term mortality after transfusion-associated non-a, non-B hepatitis. The National Heart, Lung, and Blood Institute study group N Engl J Med 327 1906-1911

[2] Buskell-Bales Z(2013)Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 1333-1342

[3] Wright EC(2014)Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection Hepatology 59 2083-2091

[4] Mohd Hanafiah K(2015)Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial Lancet Infect Dis 15 645-653

[5] Groeger J(2014)Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 1889-1898

[6] Flaxman AD(2014)Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 1483-1493

[7] Kumada H(2014)Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 1879-1888

[8] Suzuki Y(2014)Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 1993-2001

[9] Ikeda K(2016)Retrospective analysis of hepatitis C infected patients treated through an integrated care model World J Gastroenterol 22 8558-8567

[10] Mizokami M(2016)Genotype 1 hepatitis C virus and the pharmacist’s role in treatment Am J Health Syst Pharm 73 764-774

[1] Seeff LB(1992)Long-term mortality after transfusion-associated non-a, non-B hepatitis. The National Heart, Lung, and Blood Institute study group N Engl J Med 327 1906-1911

[2] Buskell-Bales Z(2013)Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 1333-1342

[3] Wright EC(2014)Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection Hepatology 59 2083-2091

[4] Mohd Hanafiah K(2015)Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial Lancet Infect Dis 15 645-653

[5] Groeger J(2014)Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 1889-1898

[6] Flaxman AD(2014)Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 1483-1493

[7] Kumada H(2014)Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 1879-1888

[8] Suzuki Y(2014)Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 1993-2001

[9] Ikeda K(2016)Retrospective analysis of hepatitis C infected patients treated through an integrated care model World J Gastroenterol 22 8558-8567

[10] Mizokami M(2016)Genotype 1 hepatitis C virus and the pharmacist’s role in treatment Am J Health Syst Pharm 73 764-774